BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Bruix J. Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;32:679-680. [PMID: 10991637 DOI: 10.1053/jhep.2000.16475] [Cited by in Crossref: 89] [Cited by in F6Publishing: 87] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 He C, Mao Y, Wang J, Song Y, Huang X, Lin X, Li S. The Predictive Value of Staging Systems and Inflammation Scores for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgical Resection: a Retrospective Study. J Gastrointest Surg 2018;22:1239-50. [PMID: 29667093 DOI: 10.1007/s11605-018-3756-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
2 Detry O, Govaerts L, Deroover A, Vandermeulen M, Meurisse N, Malenga S, Bletard N, Mbendi C, Lamproye A, Honoré P, Meunier P, Delwaide J, Hustinx R. Prognostic value of 18F-FDG PET/CT in liver transplantation for hepatocarcinoma. World J Gastroenterol 2015; 21(10): 3049-3054 [PMID: 25780305 DOI: 10.3748/wjg.v21.i10.3049] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
3 Schütte K, Zimmermann L, Bornschein J, Csepregi A, Rühl R, Ricke J, Malfertheiner P. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. Digestion. 2011;83:275-282. [PMID: 21282952 DOI: 10.1159/000320377] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
4 Cheng CH, Lee CF, Wu TH, Chan KM, Chou HS, Wu TJ, Yu MC, Chen TC, Lee WC, Chen MF. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol. 2011;9:114. [PMID: 21958080 DOI: 10.1186/1477-7819-9-114] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
5 Li Y, Ruan D, Yi H, Wang G, Yang Y, Jiang N. A three-factor preoperative scoring model predicts risk of recurrence after liver resection or transplantation in hepatocellular carcinoma patients with preserved liver function. Hepatobiliary & Pancreatic Diseases International 2015;14:477-84. [DOI: 10.1016/s1499-3872(15)60412-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
6 Broelsch CE, Frilling A, Malago M. Hepatoma—resection or transplantation. Surgical Clinics of North America 2004;84:495-511. [DOI: 10.1016/j.suc.2003.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
7 Chang L, Wang Y, Zhang J, Guo T. The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies. Oncotarget 2017;8:20418-27. [PMID: 28099898 DOI: 10.18632/oncotarget.14668] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
8 Pang Q, Bi JB, Wang ZX, Xu XS, Qu K, Miao RC, Chen W, Zhou YY, Liu C. Simple models based on gamma-glutamyl transpeptidase and platelets for predicting survival in hepatitis B-associated hepatocellular carcinoma. Onco Targets Ther 2016;9:2099-109. [PMID: 27110127 DOI: 10.2147/OTT.S101465] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
9 Stefansdottir J, Christensen E, Schiødt FV. Hepatocellular carcinoma in Danish patients: a single Copenhagen center experience. Scandinavian Journal of Gastroenterology 2017;52:768-72. [DOI: 10.1080/00365521.2017.1304985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Casella G, Cacopardo E, Rovere G, Buda CA, Cascinu S, Baldini V. Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma. J Clin Ultrasound. 2001;29:354-358. [PMID: 11424102 DOI: 10.1002/jcu.1048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
11 Miyazaki M, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, Nozawa S, Furukawa K, Takeuchi D. Surgical treatment for liver cancer. Current issues. Dig Surg. 2007;24:120-125. [PMID: 17446706 DOI: 10.1159/000101899] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
12 Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G, Tiribelli C. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med 2007;13:89-96. [PMID: 17515960 DOI: 10.2119/2006-00084.dimaso] [Cited by in Crossref: 66] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
13 Tannus RK, Almeida-Carvalho SR, Loureiro-Matos CA, Miziara-Gonzalez A, Salzedas-Netto AA, Szejnfeld D, D'Ippolito G, Pereira-Lanzoni V, Souza-Silva I. Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. PLoS One 2018;13:e0194922. [PMID: 29617435 DOI: 10.1371/journal.pone.0194922] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
14 Weber S, Jarnagin W, Duffy A, O'reilly EM, Abou-alfa GK, Blumgart L. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2008. pp. 1569-94. [DOI: 10.1016/b978-0-443-06694-8.50088-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Gao Y, Liu J, Zhao D, Diao G. A Novel Prognostic Model for Identifying the Risk of Hepatocellular Carcinoma Based on Angiogenesis Factors. Front Genet 2022;13:857215. [DOI: 10.3389/fgene.2022.857215] [Reference Citation Analysis]
16 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2015; 7(3): 406-424 [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 9.7] [Reference Citation Analysis]
17 Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology. 2011;80:373-381. [PMID: 21822028 DOI: 10.1159/000329040] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
18 Pang Q, Zhang JY, Xu XS, Song SD, Chen W, Zhou YY, Miao RC, Qu K, Liu SS, Dong YF, Liu C. The prognostic values of 12 cirrhosis-relative noninvasive models in patients with hepatocellular carcinoma. Scand J Clin Lab Invest 2015;75:73-84. [PMID: 25465804 DOI: 10.3109/00365513.2014.981759] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
19 Katsuta E, Tanaka S, Mogushi K, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Tanabe M, Arii S. Age-related clinicopathologic and molecular features of patients receiving curative hepatectomy for hepatocellular carcinoma. The American Journal of Surgery 2014;208:450-6. [DOI: 10.1016/j.amjsurg.2014.01.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
20 Takada H, Amemiya F, Yasumura T, Yoda H, Okuwaki T, Imagawa N, Shimamura N, Tanaka K, Kadokura M, Maekawa S, Enomoto N. Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma. Sci Rep 2020;10:10186. [PMID: 32576956 DOI: 10.1038/s41598-020-67147-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhang X, Qi X, Meng B, Liu C, Yu L, Wang B, Lv Y. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: Comparison of five staging systems. European Journal of Surgical Oncology (EJSO) 2010;36:718-24. [DOI: 10.1016/j.ejso.2010.05.022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
22 Zhou J, Yan T, Bi X, Zhao H, Huang Z, Zhang Y, Li Y, Feng L, Wang J, Cai J. Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy. Tumour Biol. 2013;34:1061-1070. [PMID: 23322323 DOI: 10.1007/s13277-013-0646-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
23 Wildi S, Pestalozzi BC, McCormack L, Clavien PA. Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 2004;91:400-8. [PMID: 15048738 DOI: 10.1002/bjs.4554] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
24 Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007;25:3069-3075. [PMID: 17634485 DOI: 10.1200/jco.2006.08.4046] [Cited by in Crossref: 172] [Cited by in F6Publishing: 68] [Article Influence: 11.5] [Reference Citation Analysis]
25 Schweim JK, Nonnemacher M, Jöckel KH. Heterogeneity of national legislation and practice on clinical trials with vulnerable patients based on the EU Clinical Trials Directive by the example of adults permanently incapable of giving informed consent. Ger Med Sci 2021;19:Doc03. [PMID: 33796001 DOI: 10.3205/000290] [Reference Citation Analysis]
26 Smoot RL, Nagorney DM, Chandan VS, Que FG, Schleck CD, Harmsen WS, Kendrick ML. Resection of hepatocellular carcinoma in patients without cirrhosis. Br J Surg. 2011;98:697-703. [PMID: 21280030 DOI: 10.1002/bjs.7401] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
27 Yılmaz A, Şimşek M, Hannarici Z, Büyükbayram ME, Bilici M, Tekin SB. The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib. Future Oncol 2021;17:4545-59. [PMID: 34431372 DOI: 10.2217/fon-2021-0457] [Reference Citation Analysis]
28 Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011;117:2478-2488. [PMID: 24048796 DOI: 10.1002/cncr.25791] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
29 Sharifian M, Baharvand P, Moayyedkazemi A. Liver Cancer: New Insights into Surgical and Nonsurgical Treatments. CCTR 2021;17:197-206. [DOI: 10.2174/1573394717666210219104201] [Reference Citation Analysis]
30 Basit SA, Stone CD, Gish R. Portal vein thrombosis. Clin Liver Dis. 2015;19:199-221. [PMID: 25454305 DOI: 10.1016/j.cld.2014.09.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
31 Huang J, Xu L, Luo Y, He F, Zhang Y, Chen M. The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. Med Oncol. 2014;31:883. [PMID: 24535607 DOI: 10.1007/s12032-014-0883-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
32 Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:1325-1335. [PMID: 18504614 DOI: 10.1007/s00432-008-0406-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
33 Xu LB, Wang J, Liu C, Pang HW, Chen YJ, Ou QJ, Chen JS. Staging systems for predicting survival of patients with hepatocellular carcinoma after surgery. World J Gastroenterol 2010; 16(41): 5257-5262 [PMID: 21049561 DOI: 10.3748/wjg.v16.i41.5257] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
34 Lacin S, Yalcin S, Karakas Y, Hassan MM, Amin H, Mohamed YI, Rashid A, Morris JS, Xiao L, Qayyum A, Kaseb AO. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study. J Hepatocell Carcinoma 2020;7:143-53. [PMID: 32984091 DOI: 10.2147/JHC.S258930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Thelen A, Scholz A, Benckert C, von Marschall Z, Schröder M, Wiedenmann B, Neuhaus P, Rosewicz S, Jonas S. VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma. Int J Cancer. 2008;122:2471-2481. [PMID: 18338756 DOI: 10.1002/ijc.23439] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
36 Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, D'amico F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D'amico DF. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? Journal of Hepatology 2004;40:124-31. [DOI: 10.1016/j.jhep.2003.09.027] [Cited by in Crossref: 133] [Cited by in F6Publishing: 122] [Article Influence: 7.4] [Reference Citation Analysis]
37 Pang Q, Bi JB, Xu XS, Liu SS, Zhang JY, Zhou YY, Qu K, Liu C. King's score as a novel prognostic model for patients with hepatitis B-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2015;27:1337-1346. [PMID: 26275082 DOI: 10.1097/meg.0000000000000452] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
38 Li GZ, Shen D, Li GH, Wei M, Zheng LJ, Liu ZL, Sun RQ, Zhou SJ, Zhang ZL, Gao YC. Decreased expression of serum semaphorin 3B is associated with poor prognosis of patients with hepatocellular carcinoma. Exp Ther Med 2021;21:236. [PMID: 33603844 DOI: 10.3892/etm.2021.9667] [Reference Citation Analysis]
39 Diaz-Beveridge R, Bruixola G, Lorente D, Caballero J, Rodrigo E, Segura Á, Akhoundova D, Giménez A, Aparicio J. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. Clin Transl Oncol 2018;20:322-9. [PMID: 28801777 DOI: 10.1007/s12094-017-1720-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
40 Hong YM, Yoon KT, Hwang TH, Cho M. Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma. BMC Cancer 2020;20:937. [PMID: 32993594 DOI: 10.1186/s12885-020-07105-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Zhao H, Li J, Li S, Wang Y, Zhou J, Liu L, Wang C. Comparative Analysis of Presentation and Outcome After Liver Resection of Patients With Hepatocellular Carcinoma With and Without HIV. J Acquir Immune Defic Syndr 2021;86:361-8. [PMID: 33165126 DOI: 10.1097/QAI.0000000000002561] [Reference Citation Analysis]
42 Cao Y, Jiang Z, Wang S, Zhang H, Jiang Y, Lv L. Prediction of long-term survival rates in patients undergoing curative resection for solitary hepatocellular carcinoma. Oncol Lett 2018;15:2574-82. [PMID: 29434976 DOI: 10.3892/ol.2017.7612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
43 Allen J, Venook A. Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep 2004;6:177-83. [PMID: 15066228 DOI: 10.1007/s11912-004-0047-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
44 Sauer P, Kraus TW, Schemmer P, Mehrabi A, Stremmel W, Buechler MW, Encke J. Liver Transplantation for Hepatocellular Carcinoma: Is there Evidence for Expanding the Selection Criteria? Transplantation 2005;80:S105-8. [DOI: 10.1097/01.tp.0000187107.64215.7b] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
45 Tellapuri S, Sutphin PD, Beg MS, Singal AG, Kalva SP. Staging systems of hepatocellular carcinoma: A review. Indian J Gastroenterol 2018;37:481-91. [DOI: 10.1007/s12664-018-0915-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
46 Yu L, Liu X, Wang X, Zhou D, Yan H, Xie Y, Pu Q, Zhang K, Yang Z. Nomogram for prediction of long-term survival with hepatocellular carcinoma based on NK cell counts. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100672] [Reference Citation Analysis]
47 Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'amico F, Ciarleglio FA, Bridda A, Francesco D'amico D. Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of Hepatology 2006;44:723-31. [DOI: 10.1016/j.jhep.2005.12.015] [Cited by in Crossref: 275] [Cited by in F6Publishing: 259] [Article Influence: 17.2] [Reference Citation Analysis]
48 Szklaruk J, Silverman PM, Charnsangavej C. Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma. AJR Am J Roentgenol. 2003;180:441-454. [PMID: 12540450 DOI: 10.2214/ajr.180.2.1800441] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
49 Ramaswami R, Pinato DJ, Kubota K, Ishizuka M, Arizumi T, Kudo M, Jang JW, Kim YW, Pirisi M, Allara E, Sharma R. Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. Med Oncol 2016;33:114. [PMID: 27601241 DOI: 10.1007/s12032-016-0827-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
50 Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:23-33. [PMID: 21115578 DOI: 10.1634/theoncologist.2010-s4-23] [Cited by in Crossref: 79] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
51 Wu B, Hu X, Jin H, Zhou L, Zhang D, Man Z, Wang Y, Yang S, Pang Q, Liu H, Cui P. Albumin-bilirubin and platelet-albumin-bilirubin grades for hepatitis B-associated hepatocellular carcinoma in Child-Pugh A patients treated with radical surgery: A retrospective observational study. Medicine (Baltimore) 2019;98:e17394. [PMID: 31651841 DOI: 10.1097/MD.0000000000017394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Hu S, Gan W, Qiao L, Ye C, Wu D, Liao B, Yang X, Jiang X. A New Prognostic Algorithm Predicting HCC Recurrence in Patients With Barcelona Clinic Liver Cancer Stage B Who Received PA-TACE. Front Oncol 2021;11:742630. [PMID: 34745962 DOI: 10.3389/fonc.2021.742630] [Reference Citation Analysis]
53 Anota A, Boulin M, Dabakuyo-Yonli S, Hillon P, Cercueil JP, Minello A, Jouve JL, Paoletti X, Bedenne L, Guiu B. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma. BMJ Open. 2016;6:e010696. [PMID: 27342239 DOI: 10.1136/bmjopen-2015-010696] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
54 Kubo S, Tanaka H, Shuto T, Takemura S, Yamamoto T, Uenishi T, Tanaka S, Hai S, Yamamoto S, Ichikawa T, Kodai S, Hirohashi K. Prognostic effects of causative virus in hepatocellular carcinoma according to the Japan integrated staging (JIS) score. J Gastroenterol 2005;40:972-9. [PMID: 16261434 DOI: 10.1007/s00535-005-1681-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
55 Thiesen AL. Hepatocellular Carcinoma in Adults. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 39-54. [DOI: 10.36255/exonpublications.livercancer.2021.ch2] [Reference Citation Analysis]
56 Jonas S, Mittler J, Pascher A, Theruvath T, Thelen A, Klupp J, Langrehr JM, Neuhaus P. Extended indications in living-donor liver transplantation: bile duct cancer. Transplantation. 2005;80:S101-S104. [PMID: 16286884 DOI: 10.1097/01.tp.0000187106.29908.2b] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
57 Huang J, Zhang Y, Peng Z, Gao H, Xu L, Jiao LR, Chen M. A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. J Cancer Res Clin Oncol. 2013;139:1709-1719. [PMID: 23982274 DOI: 10.1007/s00432-013-1497-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
58 Yamamoto Y, Ikoma H, Morimura R, Shoda K, Konishi H, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Kubota T, Nakanishi M, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C, Ochiai T, Otsuji E. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2015; 21(1): 246-253 [PMID: 25574098 DOI: 10.3748/wjg.v21.i1.246] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
59 Vauthey J, Ribero D, Abdalla EK, Jonas S, Bharat A, Schumacher G, Lerut J, Chapman WC, Hemming AW, Neuhaus P. Outcomes of Liver Transplantation in 490 Patients with Hepatocellular Carcinoma: Validation of a Uniform Staging after Surgical Treatment. Journal of the American College of Surgeons 2007;204:1016-27. [DOI: 10.1016/j.jamcollsurg.2006.12.043] [Cited by in Crossref: 61] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
60 Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016; 8(17): 703-715 [PMID: 27330679 DOI: 10.4254/wjh.v8.i17.703] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
61 Gu J, Zhang X, Wang Z, Cui R, Zhang J, Jia Y, Miao R, Fan H, Wang H, Li Y, Zhang J, Liu C, Qu K. Simplified nomograms based on platelet-associated models for survival prediction in Asian hepatocellular carcinoma patients after surgery. Surg Oncol 2019;30:131-8. [PMID: 31500777 DOI: 10.1016/j.suronc.2019.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
62 Faber W, Sharafi S, Stockmann M, Denecke T, Sinn B, Puhl G, Bahra M, Malinowski MB, Neuhaus P, Seehofer D. Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver. Surgery. 2013;153:510-517. [PMID: 23122930 DOI: 10.1016/j.surg.2012.09.015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
63 Mohnike K, Wieners G, Schwartz F, Seidensticker M, Pech M, Ruehl R, Wust P, Lopez-hänninen E, Gademann G, Peters N, Berg T, Malfertheiner P, Ricke J. Computed Tomography–Guided High-Dose-Rate Brachytherapy in Hepatocellular Carcinoma: Safety, Efficacy, and Effect on Survival. International Journal of Radiation Oncology*Biology*Physics 2010;78:172-9. [DOI: 10.1016/j.ijrobp.2009.07.1700] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
64 Duseja A. Staging of hepatocellular carcinoma. J Clin Exp Hepatol 2014;4:S74-9. [PMID: 25755615 DOI: 10.1016/j.jceh.2014.03.045] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
65 Chen ZH, Hong YF, Lin J, Li X, Wu DH, Wen JY, Chen J, Ruan DY, Lin Q, Dong M, Wei L, Wang TT, Lin ZX, Ma XK, Wu XY, Xu R. Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncol Lett 2017;14:705-14. [PMID: 28693224 DOI: 10.3892/ol.2017.6222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
66 Ashamalla H, Mattes MD. Radiation Oncology in the Treatment of Hepatocellular Carcinoma. In: Berliner L, Lemke HU, editors. An Information Technology Framework for Predictive, Preventive and Personalised Medicine. Cham: Springer International Publishing; 2015. pp. 93-102. [DOI: 10.1007/978-3-319-12166-6_11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Chen TW, Chu CM, Yu JC, Chen CJ, Chan DC, Liu YC, Hsieh CB. Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy. Eur J Surg Oncol. 2007;33:480-487. [PMID: 17129701 DOI: 10.1016/j.ejso.2006.10.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
68 Li BK, Huang PZ, Qiu JL, Liao YD, Hong J, Yuan YF. Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma. Diagn Pathol. 2014;9:226. [PMID: 25466449 DOI: 10.1186/s13000-014-0226-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
69 Pang Q, Zhou L, Qu K, Cui R, Jin H, Liu H. Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study. European Journal of Gastroenterology & Hepatology 2018;30:60-70. [DOI: 10.1097/meg.0000000000001021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
70 Lin ZX, Ruan DY, Jia CC, Wang TT, Cheng JT, Huang HQ, Wu XY. Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with HBV-associated hepatocellular carcinoma after curative hepatectomy. Clin Transl Oncol 2020;22:370-80. [PMID: 31201606 DOI: 10.1007/s12094-019-02137-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
71 Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122:1609-1619. [PMID: 12016426 DOI: 10.1053/gast.2002.33411] [Cited by in Crossref: 374] [Cited by in F6Publishing: 363] [Article Influence: 18.7] [Reference Citation Analysis]
72 Huo J, Wu L, Zang Y. Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma. J Cell Mol Med 2021;25:1151-65. [PMID: 33300278 DOI: 10.1111/jcmm.16181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
73 Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396-1405. [PMID: 15565571 DOI: 10.1002/hep.20486] [Cited by in Crossref: 243] [Cited by in F6Publishing: 234] [Article Influence: 13.5] [Reference Citation Analysis]
74 Schütte K, Kipper M, Kahl S, Bornschein J, Götze T, Adolf D, Arend J, Seidensticker R, Lippert H, Ricke J. Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. Digestion. 2013;87:147-159. [PMID: 23548687 DOI: 10.1159/000346743] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
75 Hsu CY, Huang YH, Su CW, Chiang JH, Lin HC, Lee PC, Lee FY, Huo TI, Lee SD. Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency. J Clin Gastroenterol. 2010;44:e171-e177. [PMID: 20048685 DOI: 10.1097/mcg.0b013e3181c88235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
76 Yen Y, Changchien C, Wang J, Kee K, Hung C, Hu T, Lee C, Lin C, Wang C, Chen T, Huang Y, Lu S. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Digestive and Liver Disease 2009;41:431-41. [DOI: 10.1016/j.dld.2008.11.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
77 Shimizu T, Ishizuka M, Suzuki T, Tanaka G, Shiraki T, Sakuraoka Y, Matsumoto T, Kato M, Aoki T, Kubota K. The Value of the C-Reactive Protein-to-Albumin Ratio is Useful for Predicting Survival of Patients with Child-Pugh Class A Undergoing Liver Resection for Hepatocellular Carcinoma. World J Surg 2018;42:2218-26. [PMID: 29288307 DOI: 10.1007/s00268-017-4446-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
78 Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med. 2007;13:89-96. [PMID: 17515960 DOI: 10.2119/2006-00084.di] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Liu Y, Liu R, Wang P, Li S, Shen H. Percutaneous implantation of 125iodine seeds for treatment of portal vein tumor thrombosis in hepatocellular carcinoma. Med Oncol 2015;32. [DOI: 10.1007/s12032-015-0657-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
80 Tanriverdi O. A discussion of serum albumin level in advanced-stage hepatocellular carcinoma: a medical oncologist's perspective. Med Oncol. 2014;31:282. [PMID: 25316265 DOI: 10.1007/s12032-014-0282-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
81 Dilou N, Patouillard B, Audigier JC. [Staging systems in hepatocellular carcinoma]. Gastroenterol Clin Biol 2004;28:359-66. [PMID: 15146151 DOI: 10.1016/s0399-8320(04)94936-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
82 Zhao LY, Yang DD, Ma XK, Liu MM, Wu DH, Zhang XP, Ruan DY, Lin JX, Wen JY, Chen J, Lin Q, Dong M, Qi JJ, Hu PS, Zeng ZL, Chen ZH, Wu XY. The Prognostic Value of aspartate aminotransferase to lymphocyte ratio and systemic immune-inflammation index for Overall Survival of Hepatocellular Carcinoma Patients Treated with palliative Treatments. J Cancer 2019;10:2299-311. [PMID: 31258733 DOI: 10.7150/jca.30663] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
83 Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs 2008;26:265-72. [PMID: 18196204 DOI: 10.1007/s10637-007-9103-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
84 Chen L, Yu CX, Zhong BY, Zhu HD, Jin ZC, Zhu GY, Zhang Q, Ni CF, Teng GJ. Development of TACE Refractoriness Scores in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:615133. [PMID: 33981722 DOI: 10.3389/fmolb.2021.615133] [Reference Citation Analysis]
85 Mathibe LJ. Drop-out rates of cancer patients participating in longitudinal RCTs. Contemp Clin Trials 2007;28:340-2. [PMID: 17449332 DOI: 10.1016/j.cct.2007.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
86 Zhao JJ, Yan T, Zhao H, Zhou JG, Huang Z, Zhang YF, Li Y, Li ZY, Bi XY, Cai JQ. Evaluation of eight different clinical staging systems associated with overall survival of chinese patients with hepatocellular carcinoma. Chin Med J (Engl) 2015;128:316-21. [PMID: 25635426 DOI: 10.4103/0366-6999.150095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
87 Pang Q, Zhang JY, Xu XS, Song SD, Qu K, Chen W, Zhou YY, Miao RC, Liu SS, Dong YF, Liu C. Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence. World J Gastroenterol 2015; 21(18): 5607-5621 [PMID: 25987786 DOI: 10.3748/wjg.v21.i18.5607] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
88 Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23:445-452. [PMID: 17683486 DOI: 10.1111/j.1440-1746.2007.05075.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
89 Befeler A, Di Bisceglie AM. Treatment of hepatocellular carcinoma. Viruses and Liver Cancer. Elsevier; 2002. pp. 161-72. [DOI: 10.1016/s0168-7069(02)06074-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
90 Zhang H, Yao M, Wu W, Qiu L, Sai W, Yang J, Zheng W, Huang J, Yao D. Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma. Tumour Biol. 2015;36:9373-9383. [PMID: 26109000 DOI: 10.1007/s13277-015-3678-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
91 Hansmann J, Ray CE Jr. Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology. Semin Intervent Radiol 2017;34:213-9. [PMID: 28579689 DOI: 10.1055/s-0037-1602757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
92 Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T. Review of current staging systems for hepatocellular carcinoma. Hepatology Research 2007;37:S210-5. [DOI: 10.1111/j.1872-034x.2007.00187.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]